http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103298344-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2011-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103298344-B |
| titleOfInvention | The coupled kinase inhibitor of whole catenin |
| abstract | Describe some compounds, and described compound is by treating to curee's drug administration composition or preventing the purposes in the method for the cancer in curee, the compound of the contained I of described pharmaceutical composition or its medicinal acceptable salt.n compound described in I also can be used for the coupled kinases of whole catenin in T suppression cell, and it has impact to Akt signal transduction path. |
| priorityDate | 2010-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 91.